NCT03398915 2026-03-31
EUROSPIN
Bergman Clinics
Active not recruiting
Clinical Trials
15 trialsNCT05912400 2025-05-08
Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
University of Arkansas
Completed
NCT02392078 2025-04-24
LAANTERN
Monteris Medical
Completed
NCT04097535 2024-11-21
Measuring Fatty Acid Oxidation in Gliomas Using 18F-FPIA PET/MRI
Imperial College London
Completed
NCT04753658 2024-09-23
Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
Pfizer
Terminated
NCT03652181 2024-06-27
CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
University of Chicago
Completed
NCT01651078 2024-04-15
LAASR
Monteris Medical
Completed
NCT02060890 2023-12-12
TGEN
University of California, San Francisco
Completed
NCT02965144 2020-06-04
Long Term Survivors of High-grade Glioma and Their Caregivers
Rigshospitalet, Denmark
Completed
NCT02276053 2020-06-01
VIBES
UCB Pharma
Completed
NCT02693171 2019-08-05
Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
United Therapeutics
Terminated
NCT02031237 2019-07-26
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
University of Michigan Rogel Cancer Center
Completed
NCT00704808 2015-09-09
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
Merck Sharp & Dohme LLC
Completed
NCT00725010 2015-09-09
Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
Merck Sharp & Dohme LLC
Completed
NCT00723827 2015-01-30
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Merck Sharp & Dohme LLC
Completed